Age Is But a Number? An Exploration of Age Differences in Episodic Volunteering

VOLUNTAS: International Journal of Voluntary and Nonprofit Organizations - Age has long been understood as a strong demographic determinant of volunteering. However, to date, limited literature...     

中美科幻小说的创作及研究进路考察——基于1990年代以来的科幻文学视域

科幻小说诞生于19世纪的欧洲,是科技与文学的一种融合.这种文学形式,以其特有的叙事方式,承载着人类探求未来世界、认知未来社会的精神寄望与诉求.作为世界的共有资源,中美两国的科幻小说在其创作及研究的进路中有着较大的距离差别.美国的科幻小说虽较晚于启蒙国英国,但作为科学技术大国、强国,其创作和研究的超越提速是较大的,出现了诸如罗伯特·海因莱因及《星船伞兵》、艾萨克·阿西莫夫及"基地"系列、"机器人"系列等等这样的科幻小说巨头及巨作,研究的深入跟进亦趋于世界前列;相对而言,中国科幻文坛虽曾有过20世纪50年代的辉煌,诞生了郑文光等名家,但中国现代科幻小说的创作及研究是滞后的.20世纪90年代以降,刘慈欣的《三体》三部曲、王晋康的《逃出母宇宙》等科幻大作的出现,使中国科幻小说的创作及研究吸引了世界的目光,其影响在改变着这一滞后的局面.世界科幻王国终于有了中国的声音.     

1950年代:“本质—特征论”文学定义的形成及影响

1950年代形成了"本质—特征论"的文学定义,即先界定文学的意识形态本质,再界定文学是用形象的方式来反映社会生活、体现意识形态的特征。这一定义的思维方式是先界定事物的普遍性,再界定事物的特殊性,突出事物的普遍性关联,轻视事物的独特性质的揭示,使得文学研究本应着重研究文学的特殊性成为空话,不利于认识文学自身的规律。1980年代的文学审美论试图突破这种定义方式,但1990年代以来,反本质主义的文学语境论再次回到从事物的关联性定义事物的思维老路,文学自身本质问题受到质疑,弱化了文学与审美关联的重要性与必要性。     

A new long-term survival model with dispersion induced by discrete frailty

Lifetime Data Analysis - Frailty models are generally used to model heterogeneity between the individuals. The distribution of the frailty variable is often assumed to be continuous. However, there...     

Towards Uniformly Efficient Trend Estimation Under Weak/Strong Correlation and Non‐stationary Volatility

In this paper, we consider the deterministic trend model where the error process is allowed to be weakly or strongly correlated and subject to non‐stationary volatility. Extant estimators of the trend coefficient are analysed. We find that under heteroskedasticity, the Cochrane–Orcutt‐type estimator (with some initial condition) could be less efficient than Ordinary Least Squares (OLS) when the process is highly persistent, whereas it is asymptotically equivalent to OLS when the process is less persistent. An efficient non‐parametrically weighted Cochrane–Orcutt‐type estimator is then proposed. The efficiency is uniform over weak or strong serial correlation and non‐stationary volatility of unknown form. The feasible estimator relies on non‐parametric estimation of the volatility function, and the asymptotic theory is provided. We use the data‐dependent smoothing bandwidth that can automatically adjust for the strength of non‐stationarity in volatilities. The implementation does not require pretesting persistence of the process or specification of non‐stationary volatility. Finite‐sample evaluation via simulations and an empirical application demonstrates the good performance of proposed estimators.     

川东北地区须家河组二段储层差异性分析

随着勘探程度的深入，为了扩大四川盆地天然气勘探领域、寻找新的勘探接替区，四川盆地的勘探区域由盆内逐渐向盆缘延伸。在这种背景下，川东北地区须家河组二段相继取得新的勘探成果，但在勘探开发过程中逐渐暴露了诸如区块之间气井产能差异大，储层的碎屑组分、结构及厚度、物性、孔隙结构差异明显等问题，制约了勘探开发的步伐。针对上述问题，根据岩芯观察描述、分析化验资料及测井解释成果，从沉积、成岩方面入手，对比剖析了川东北龙岗和营山地区须二段储层特征的差异性及其成因，认为远离物源区和高能水体的反复淘洗是造成储层差异性的首要因素，强烈的压实作用和多期石英加大对储层差异性起关键作用，自生绿泥石衬边胶结和长石选择性溶蚀最终决定了储层差异性。从而解释了气藏勘探开发中遇到的诸多问题，对有效指导该区的下一步勘探开发工作具有重要意义。     

Inference and Decision Making for 21st-Century Drug Development and Approval

ABSTRACT

The cost and time of pharmaceutical drug development continue to grow at rates that many say are unsustainable. These trends have enormous impact on what treatments get to patients, when they get them and how they are used. The statistical framework for supporting decisions in regulated clinical development of new medicines has followed a traditional path of frequentist methodology. Trials using hypothesis tests of “no treatment effect” are done routinely, and the p-value < 0.05 is often the determinant of what constitutes a “successful” trial. Many drugs fail in clinical development, adding to the cost of new medicines, and some evidence points blame at the deficiencies of the frequentist paradigm. An unknown number effective medicines may have been abandoned because trials were declared “unsuccessful” due to a p-value exceeding 0.05. Recently, the Bayesian paradigm has shown utility in the clinical drug development process for its probability-based inference. We argue for a Bayesian approach that employs data from other trials as a “prior” for Phase 3 trials so that synthesized evidence across trials can be utilized to compute probability statements that are valuable for understanding the magnitude of treatment effect. Such a Bayesian paradigm provides a promising framework for improving statistical inference and regulatory decision making.